| | |
| |  | CRITICAL UPDATE: Wednesday, 6:47 a.m.
Dear Startup Investor,
Things are starting to happen fast.
A game-changing breakthrough we call the "Super Vaccine" is now starting production.
In trials, it has already generated an immune response in humans, and the FDA has granted it a Fast-Track Designation.
The administration has infused the company with $483 million to expedite approval.
And now, not only has a contract for 10 billion doses been signed... but production is now underway for the viable "Super Vaccine!"
Bottom line: Not only could the "Super Vaccine" bring COVID-19 to its knees, it could also ignite a staggering 58,300% revenue surge for one tiny $60 million company.
Go here now for the full story.
Sincerely,
Bob Keppel
Publisher, The Startup Investor
| Please do not reply to this email. It was sent from an unmonitored mailbox.
You are receiving this e-mail at phanphuongthanh89.822152@blogger.com, as part of your subscription to The Startup Investor. To remove your email from this list: unsubscribe here.
To cancel, or for any other questions or requests, please contact our Customer Service team:
Online
Phone: 866-310-1498 (North America) 410-501-5876 (International)
Mail: The Startup Investor | Attn: Member Services | 1125 N Charles Street | Baltimore, MD 21201
Our Customer Service team is available Monday ‑ Friday between 9:00 AM and 5:00 PM ET.
© 2020 Angels & Entrepreneurs. All Rights Reserved.
Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice.
We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.
Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of: Angels & Entrepreneurs. 1125 N Charles Street, Baltimore, MD 21201.
Website | Privacy Policy | Terms & Conditionshttp://link.e.angelsandentrepreneurs.com/wf/unsubscribe?upn=SVR9z3LgXEwEIVbUkFIuhfIKPV96lSE9UseWeXZ52MI4WY4eEn-2FXQBTN4MGeOz0GseIyndgO8daCHIwjmPi0EySCaAsypuV8RNEMBC-2FVlkhIHWMm1hw0uSXu4GkwGu9TAayNV8TQjBBSMH1t8f3YsH-2BEq2eiGipWZqe-2B8-2FM83BW0PLWRHvzNABv2mbfX6aOks7patNiOiTJE-2FYTudhQzw2jOkB7G5uFZHonJq9W73cVLBxDXT-2BqOgyPQSjrbqu0-2BzzzqnVYlx4bePWxFuBBn9vZNm6Ef9G9jKhOoyZmsVKZKnVTEw0WQH75Qiyp8-2FPXmG3X2x4lijBSk3-2B4qBPaMMAJSg4oAr8PSCb0Yx9iCzl3X4u0r43RAhSkZ6bqETbi6aM4BYtn4jdNBhSBvyhpo6zjeQmP4YZnQoZ27bpaRrcH0d9owxZI7XKY5fi1IgPQX58gm1OBLnthB3hGcDPfHLeuRcE70iVYdy8IYYjGclbXj56ICA27eToUZU7RL4Rq-2FuXmD7PNMr0LoFBkEe2yeng23uKASzbN4VudE-2FiWCwKmsfa5J-2FlPaCC6e97LjLTvF72VU2JJPg4XATOv9po-2FNRrZpVeP-2Flv-2FtNNIPAaxrLmaE0v6dBVL3kFZSy7CRg6rK8ByHe0cFeg4h7FCRAfaxqhI3H2fEXh1ZUak99Eyf6nl8yaMuSR3Dy2oktYd53OBEwT0cPzw6O-2BZjIi3SJrxkMuV3nXjgg-2BiyhxMVMwxE0jNWpE6Ve4XZ9sb8ZTdOkYSZn1gt08-2FNA-2BmMNderpwtJvLWNxEe3jyGWiaNwqgbymCSEWkRekN3spPX6g4ZVfh0YzzYjaHyNHPi66Iw0RRMFfDN2mObegw58fqUD1-2F-2FtFoQoDRQ4U9h-2B73RuX3Lvtc4D221No35orooRvKPDmkjZfNV2LF6JGhFWXxYZmILhlRbdzvR9fkktazDytiIGFKSZ-2FVioIqneXqXkp4Tn8aokRw-3D-3D |
|
No comments:
Post a Comment